Table 1.

Determinations of infectious units per million (IUPM) cells with or without raltegravir using different criteria

Study subject	With raltegravir day 14		Without raltegravir day 14		Amplification day 14 without raltegravir		Amplification AUC without raltegravir
	IUPM	95% CI	IUPM	95% CI	IUPM	95% CI	IUPM	95% CI
197	0.7	0.3–1.8	7.8	3.8–15.9	5.7	2.9–11.2	4.8	2.4–9.6
215	9.9	5.0–19.5	18.3	9.5–35.2	6.5	3.5–12.2	1.5	0.8–2.8
216	0.1	0.3–0.3	1.1	0.5–2.2	1.2	0.6–2.5	1.2	0.6–2.5
217	1.1	0.5–2.2	0.5	0.2–1.4	0.5	0.2–1.4	0.9	0.4–1.9
219	15.7	8.1–30.5	18.7	9.2–38.2	7.1	3.5–14.2	14.4	7.6–27.5

IUPM were calculated as described in Methods. Column 1: Subject number. Column 2: IUPM with a positive well defined as containing > 100 copies HIV RNA per ml on day 14 in the presence of raltegravir. Column 3: IUPM with a positive well defined as containing > 100 copies HIV RNA per ml on day 14 in the absence of raltegravir. Two criteria were used to define amplification (replication competence) in the absence of raltegravir: Column 4: A well was defined as positive on day 14 without raltegravir when the value was greater than the mean plus 5 SD of the 6 wells in the presence of raltegravir. Column 5: The criterion for a positive well assessing amplification by AUC without raltegravir used the mean and SD of the area under the curve for the 2 weeks of measurements for all six wells in that dilution in the presence of raltegravir